Riskpilot← Back to searchSign inGet full accessONCOGENE AS
ASActiveOrg 825818642Gunnar Randers' Vei 12, 2007 KjellerTechnical testing and analysis · NACE 7120Est. 20202 employeesoncogene.no
Revenue 2024
NOK 644K
EBITDA margin
33.0%
+567% vs 2023
Equity ratio
14.6%
Financial strength
Net profit 2024
NOK 57K
+224% vs 2023
| Revenue | NOK 644K | — |
| EBITDA | NOK 213K | +567% |
| Net profit | NOK 57K | +224% |
| Total assets | NOK 7,5M | +465% |
| Equity | NOK 1,1M | +2895% |
| Employees | 2 | — |
Legal name
ONCOGENE AS
Org number
825818642
Legal form
Aksjeselskap
NACE code
7120 · Technical testing and analysis
Founded
21. oktober 2020
Share capital
NOK 31 900
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller daglig leder alene.
Company purpose
Tilby genetiske analyser for privatpersoner, forskning og annen næringsvirksomhet, samt bioinformatikk analyse av alle slag for presisjonsmedisin og personalisert terapi, og annet som naturlig faller sammen med dette.
Address
Gunnar Randers' Vei 12, 2007 Kjeller
Website
oncogene.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 78 | 0 | 644 |
| Staff expenses | −0 | −64 | −0 | −124 |
| EBITDA | 0 | −5 | −46 | 213 |
| Depreciation & amort. | −0 | −0 | −0 | −11 |
| EBIT | 0 | −5 | −46 | 201 |
| Net financials | 0 | −0 | −0 | −144 |
| Profit before tax | 0 | −5 | −46 | 57 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | 0 | −5 | −46 | 57 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 30 | 90 | 1 330 | 7 521 |
| Equity | 30 | −4 | 37 | 1 101 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 95 | 244 | 6 420 |
| Total debt | 0 | 95 | 244 | 6 420 |
EBITDA margin
33.0%
This company
15.8%
Market median
+109% vs market
20212024
Equity ratio
14.6%
This company
38.2%
Market median
-62% vs market
20212024
Return on equity
5.2%
This company
18.4%
Market median
-72% vs market
20212024
Net profit margin
8.9%
This company
8.1%
Market median
+10% vs market
20212024
Asset turnover
0.09×
This company
1.12×
Market median
-92% vs market
20212024
Debt / equity
5.83×
This company
0.62×
Market median
-840% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-09-29 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MB Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ONCOGENE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Bjelke-Holtermann Duesund | Chief Executive Officer | 0 companies |
| Charitra Kumar Mishra | Board of Directors | 0 companies |
| Ida Christine Filtenborg Hansen | Board of Directors | 0 companies |
| Klaus Hermann Beiske | Board of Directors | 0 companies |
| Tore Helge Rismyhr | Board of Directors | 0 companies |